BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes. The study, published in ...
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...
Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...
Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...
LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results